Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Exemptions From Substantial Equivalence Requirements for Tobacco Products, 26123-26125 [2019-11658]
Download as PDF
jbell on DSK3GLQ082PROD with NOTICES
Federal Register / Vol. 84, No. 108 / Wednesday, June 5, 2019 / Notices
FDA has based these estimates on
information it now has available from
interactions with the industry,
information related to other regulated
products, and FDA expectations
regarding the tobacco industry’s use of
the section 905(j) pathway to market
their products. Table 1 describes the
annual reporting burden as a result of
the implementation of the substantial
equivalence requirements of sections
905(j)(1)(A)(i) and 910(a) of the FD&C
Act for an SE application.
FDA estimates that 683 respondents
will prepare and submit 683 section
905(j)(1)(A)(i) SE Reports each year. In
addition, anyone submitting an SE
Report is required to submit an
environmental assessment (EA) under
21 CFR 25.40. The burden for
environmental reports has been
included in the burden per response for
each type of SE report. Based on FDA’s
experience with EAs for currently
regulated tobacco products, we expect
industry to spend 80 hours to prepare
an environmental assessment for a SE
Report. Thus, FDA estimates that it will
take a manufacturer approximately 300
hours per report to prepare an SE Report
and the EA for a new tobacco product,
which is a total of 204,900 hours each
year.
In addition, we estimate receiving 456
Full SE Bundled Reports at 90 hours per
submission for a total of 41,040 hours
each year.
FDA estimates that it will receive 239
Product Quantity Change SE Reports
each year and that it will take a
manufacturer approximately 87 hours to
prepare this report for a total of 20,793
hours. This includes time to prepare the
environmental assessment, which FDA
believes will take less time due to the
typically more limited modification(s)
included in a Product Quantity Change
SE Report. We estimate receiving 192
Product Quantity Change Bundled SE
Reports each year at approximately 62
hours per submission for a total of
11,904 hours; this number excludes the
time for the initial SE Report, which
was previously accounted for.
Therefore, FDA estimates the annual
burden for submission of SE
information will be 278,637 hours. This
is an increase of 106,759 hours from the
currently approved burden. We attribute
this increase to an increase in the
number of SE Reports we expect related
to Deemed products (e.g., based on the
initial registration and listing
information).
VerDate Sep<11>2014
19:03 Jun 04, 2019
Jkt 247001
Dated: May 30, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–11657 Filed 6–4–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1588]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Exemptions From
Substantial Equivalence Requirements
for Tobacco Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by July 5,
2019.
SUMMARY:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0684. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Exemptions From Substantial
Equivalence Requirements for Tobacco
Products
OMB Control Number 0910–0684—
Extension
On June 22, 2009, the Family
Smoking Prevention and Tobacco
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
26123
Control Act (Tobacco Control Act) (Pub.
L. 111–31) was signed into law. The
Tobacco Control Act amended the
Federal Food, Drug, and Cosmetic Act
(FD&C Act) by adding a chapter granting
FDA important authority to regulate the
manufacture, marketing, and
distribution of tobacco products to
protect the public health generally and
to reduce tobacco use by minors.
The FD&C Act, as amended by the
Tobacco Control Act, requires that
before a new tobacco product may be
introduced or delivered for introduction
into interstate commerce, the new
tobacco product must undergo
premarket review by FDA. FDA must
issue an order authorizing the
commercial distribution of the new
tobacco product or find the product
exempt from the requirements of
substantial equivalence under section
910(a)(2)(A) of the FD&C Act, before the
product may be introduced into
commercial distribution (section 910 of
the FD&C Act (21 U.S.C. 387j)).
The Tobacco Control Act also gave
FDA the authority to issue a regulation
deeming all other products that meet the
statutory definition of a tobacco product
to be subject to Chapter IX of the FD&C
Act (section 901(b) (21 U.S.C. 387a(b))).
On May 10, 2016, FDA issued that rule,
extending FDA’s tobacco product
authority to all products that meet the
definition of tobacco product in the law
(except for accessories of newly
regulated tobacco products), including
electronic nicotine delivery systems,
cigars, hookah, pipe tobacco, nicotine
gels, dissolvables that were not already
subject to the FD&C Act, and other
tobacco products that may be developed
in the future (81 FR 28974 at 28976,
May 10, 2016) (‘‘the final deeming
rule’’)).
FDA has established a pathway for
manufacturers to request exemptions
from the substantial equivalence
requirements of the FD&C Act in
§ 1107.1 (21 CFR 1107.1) of the
Agency’s regulations. As described in
§ 1107.1(a), FDA may exempt tobacco
products that are modified by adding or
deleting a tobacco additive, or
increasing or decreasing the quantity of
an existing tobacco additive, from the
requirement of demonstrating
substantial equivalence if the Agency
determines that: (1) The modification
would be a minor modification of a
tobacco product that can be sold under
the FD&C Act; (2) a report
demonstrating substantial equivalence
is not necessary to ensure that
permitting the tobacco product to be
marketed would be appropriate for the
protection of public health; and (3) an
exemption is otherwise appropriate.
E:\FR\FM\05JNN1.SGM
05JNN1
26124
Federal Register / Vol. 84, No. 108 / Wednesday, June 5, 2019 / Notices
Section 1107.1(b) states that a request
for exemption under section 905(j)(3) of
the FD&C Act (21 U.S.C. 387e(j)(3)) may
be made only by the manufacturer of a
legally marketed tobacco product for a
minor modification to that tobacco
product and that the manufacturer must
submit the request and all information
supporting it to FDA. The request must
be made in an electronic format that
FDA can process, review, and archive
(or a written request must be made by
the manufacturer explaining in detail
why the manufacturer cannot submit
the request in an electronic format and
requesting an alternative means of
submission to the electronic format).
An exemption request must contain:
(1) The manufacturer’s address and
contact information; (2) identification of
the tobacco product(s); (3) a detailed
explanation of the purpose for the
modification; (4) a detailed description
of the modification, including a
statement as to whether the
modification involves adding or
deleting a tobacco additive, or
increasing or decreasing the quantity of
the existing tobacco additive; (5) a
detailed explanation of why the
modification is a minor modification of
a tobacco product that can be sold under
the FD&C Act; (6) a detailed explanation
of why a report under section 905(j)(1)
of the FD&C Act intended to
demonstrate substantial equivalence is
not necessary to ensure that permitting
the tobacco product to be marketed
would be appropriate for protection of
the public health; (7) a certification (i.e.,
a signed statement by a responsible
official of the company) summarizing
the supporting evidence and providing
the rationale for the official’s
determination that the modification
does not increase the tobacco product’s
appeal to or use by minors, toxicity,
addictiveness, or abuse liability; (8)
other information justifying an
exemption; and (9) an environmental
assessment (EA) under part 25 (21 CFR
part 25) prepared in accordance with
the requirements of § 25.40.
The National Environmental Policy
Act of 1969 (NEPA) (42 U.S.C. 4321–
4347) states national environmental
objectives and imposes upon each
Federal Agency the duty to consider the
environmental effects of its actions.
Section 102(2)(C) of NEPA requires the
preparation of an environmental impact
statement for every major Federal action
that will significantly affect the quality
of the human environment.
FDA’s NEPA regulations are
contained in part 25. All applications
for exemption from substantial
equivalence require the submission of
an EA. An EA provides information that
is used to determine whether an FDA
action could result in a significant
environmental impact. Section 25.40(a)
and (c) specifies the content
requirements for EAs for nonexcluded
actions.
The information required by
§ 1107.1(b) is submitted to FDA so FDA
can determine whether an exemption
from substantial equivalence to the
product is appropriate for the protection
of the public health. Section 1107.1(c)
states that FDA will review the
information submitted and determine
whether to grant or deny an exemption
based on whether the criteria in section
905(j)(3) of the FD&C Act are met. FDA
may request additional information if
necessary to make a determination and
may consider the exemption request
withdrawn if the information is not
provided within the requested
timeframe.
Section 905(j)(1)(A)(ii) of the FD&C
Act states that if an exemption has been
requested and granted, a report must be
submitted to FDA that demonstrates that
the tobacco product is modified within
the meaning of section 905(j)(3), the
modifications are to a product that is
commercially marketed and in
compliance with the requirements of the
FD&C Act, and all of the modifications
are covered by exemptions granted by
the Secretary of Health and Human
Services (the Secretary) under section
905(j)(3).
In the Federal Register of September
13, 2018 (83 FR 46501) FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. Two PRA related
comments were received, which
inquired about how FDA formulated the
PRA estimates. In response to the
questions related to the PRA estimates,
these estimates are based on our
experience. To date, the annual number
of exemption requests has been lower
than the estimate of 812 respondents in
this notice (https://
www.accessdata.fda.gov/scripts/
fdatrack/view/track.cfm?
program=ctp&id=%20CTP-OS-totalexemption-from-SE-since-ProgramInception), but the Agency expects that
the number of exemption requests could
increase as applicants begin to submit
such requests for tobacco products
subject to the final deeming rule. The
estimated number of respondents is
intended to reflect that potential. As
noted in the comments, the exemption
request is anticipated to take less time
than the other premarket applications,
and FDA believes that 24 hours average
burden per response reflects the
experience to date.
Along with commenting on the PRA
estimates, these comments also state
that the Agency should provide
additional details on exemption
requests and develop categories of
exemptions. FDA appreciates these
comments but notes that consideration
of such new processes is outside the
scope of the present information
collection. FDA will continue to
consider these comments as appropriate
in future rulemakings.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
21 CFR section and activity
Number of
responses per
respondent 2
Total annual
responses
Average
burden per
response
(in hours)
Total hours
jbell on DSK3GLQ082PROD with NOTICES
§ 1107.1(b) Optional Preparation of Tobacco Product Exemption From Substantial Equivalence Request Including § 25.40 Preparation of
an Environmental Assessment
21 CFR 1107.1(b)—Preparation of tobacco product exemption from substantial equivalence request and 21
CFR 25.40—Preparation of an environmental assessment ..................................................................................
812
1
812
24
19,488
Total Hours (§ 1107.1(b)) ..............................................
........................
........................
........................
........................
19,488
VerDate Sep<11>2014
19:03 Jun 04, 2019
Jkt 247001
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
E:\FR\FM\05JNN1.SGM
05JNN1
26125
Federal Register / Vol. 84, No. 108 / Wednesday, June 5, 2019 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued
Number of
respondents
21 CFR section and activity
Number of
responses per
respondent 2
Total annual
responses
Average
burden per
response
(in hours)
Total hours
§ 1107.1(c) Preparation of Additional Information for Tobacco Product Exemption From Substantial Equivalence Request
21 CFR 1107.1(c)—Preparation of additional information
for tobacco product exemption from substantial equivalence request ....................................................................
244
1
244
3
732
Total Hours (§ 1107.1(c)) ..............................................
........................
........................
........................
........................
732
Section 905(j)(1)(A)(ii) of the FD&C Act: If exemption granted, report submitted to demonstrate tobacco product is modified under section 905(j)(3), modifications are to a product that is commercially marketed and compliant, and modifications covered by exemptions granted by Secretary under section 905(j)(3)
Abbreviated report submitted to demonstrate tobacco
product is modified under section 905(j)(3), modifications are to a product that is commercially marketed and
compliant, and modifications covered by exemptions
granted by Secretary under section 905(j)(3) ..................
Total Hours (section 905(j)(1)(A)(ii)) of the FD&C Act
Total Hours Exemptions From Substantial
Equivalence Requirements ................................
jbell on DSK3GLQ082PROD with NOTICES
1 There
1217
1
1217
3
3,651
........................
........................
........................
........................
3,651
........................
........................
........................
........................
23,871
are no capital costs or operating and maintenance costs associated with this collection of information.
FDA estimates that we will receive
812 exemption requests under
§ 1107.1(b) for 24 hours per response
including EA for a total of 19,488 hours.
Since an EA is required for each
§ 1107.1(b) (Optional Preparation of
Tobacco Product Exemption From
Substantial Equivalence Request), the
burden per response for EAs (12 hours)
has been combined with the 12 hours
for an SE request for a total of 24 hours
per response.
FDA further estimates that we will
receive 244 submissions requiring
additional information in support of the
initial exemption request, and it is
expected that it will take an average of
3 hours to prepare the additional
information for a total of 732 hours.
FDA estimates that 1,217 respondents
will prepare 1,217 responses and each
response will take approximately 3
hours to prepare, as required by section
905(j)(1)(A)(ii) of the FD&C Act, for a
total of 3,651 hours.
This collection of information
requires a manufacturer to submit a
report at least 90 days prior to making
an introduction or delivery for
introduction into interstate commerce
for commercial distribution of a tobacco
product. Section 905(j)(1)(A)(ii) of the
FD&C Act states that if an exemption
has been requested and granted, the
manufacturer must submit to FDA a
report that demonstrates that the
tobacco product is modified within the
meaning of section 905(j)(3), the
modifications are to a product that is
VerDate Sep<11>2014
19:03 Jun 04, 2019
Jkt 247001
commercially marketed and in
compliance with the requirements of the
FD&C Act, and all the modifications are
covered by exemptions granted by the
Secretary under section 905(j)(3). FDA
estimates the total hours for exemptions
from Substantial Equivalence
Requirements will be 23,871 hours.
FDA’s estimates are based on full
analysis of economic impacts and
information gathered from other FDAregulated products. Based on a review of
the currently approved information
collection, we have made no
adjustments to our burden estimate.
Dated: May 30, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–11658 Filed 6–4–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: Preventing Opioid Use Disorder in
Older Adolescents and Young Adults (ages
16–30) (UG3/UH3 Clinical Trial Required).
Date: June 11, 2019.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: Coordinating Center to Support
NIDA Preventing Opioid Use Disorder in
Older Adolescents and Young Adults (ages
16–30) Initiative (U24 Clinical Trial Not
Allowed).
Date: June 12, 2019.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
E:\FR\FM\05JNN1.SGM
05JNN1
Agencies
[Federal Register Volume 84, Number 108 (Wednesday, June 5, 2019)]
[Notices]
[Pages 26123-26125]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-11658]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1588]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Exemptions From
Substantial Equivalence Requirements for Tobacco Products
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by July 5,
2019.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: 202-395-7285, or emailed to [email protected]. All
comments should be identified with the OMB control number 0910-0684.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
[email protected].
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Exemptions From Substantial Equivalence Requirements for Tobacco
Products
OMB Control Number 0910-0684--Extension
On June 22, 2009, the Family Smoking Prevention and Tobacco Control
Act (Tobacco Control Act) (Pub. L. 111-31) was signed into law. The
Tobacco Control Act amended the Federal Food, Drug, and Cosmetic Act
(FD&C Act) by adding a chapter granting FDA important authority to
regulate the manufacture, marketing, and distribution of tobacco
products to protect the public health generally and to reduce tobacco
use by minors.
The FD&C Act, as amended by the Tobacco Control Act, requires that
before a new tobacco product may be introduced or delivered for
introduction into interstate commerce, the new tobacco product must
undergo premarket review by FDA. FDA must issue an order authorizing
the commercial distribution of the new tobacco product or find the
product exempt from the requirements of substantial equivalence under
section 910(a)(2)(A) of the FD&C Act, before the product may be
introduced into commercial distribution (section 910 of the FD&C Act
(21 U.S.C. 387j)).
The Tobacco Control Act also gave FDA the authority to issue a
regulation deeming all other products that meet the statutory
definition of a tobacco product to be subject to Chapter IX of the FD&C
Act (section 901(b) (21 U.S.C. 387a(b))). On May 10, 2016, FDA issued
that rule, extending FDA's tobacco product authority to all products
that meet the definition of tobacco product in the law (except for
accessories of newly regulated tobacco products), including electronic
nicotine delivery systems, cigars, hookah, pipe tobacco, nicotine gels,
dissolvables that were not already subject to the FD&C Act, and other
tobacco products that may be developed in the future (81 FR 28974 at
28976, May 10, 2016) (``the final deeming rule'')).
FDA has established a pathway for manufacturers to request
exemptions from the substantial equivalence requirements of the FD&C
Act in Sec. [thinsp]1107.1 (21 CFR 1107.1) of the Agency's
regulations. As described in Sec. [thinsp]1107.1(a), FDA may exempt
tobacco products that are modified by adding or deleting a tobacco
additive, or increasing or decreasing the quantity of an existing
tobacco additive, from the requirement of demonstrating substantial
equivalence if the Agency determines that: (1) The modification would
be a minor modification of a tobacco product that can be sold under the
FD&C Act; (2) a report demonstrating substantial equivalence is not
necessary to ensure that permitting the tobacco product to be marketed
would be appropriate for the protection of public health; and (3) an
exemption is otherwise appropriate.
[[Page 26124]]
Section 1107.1(b) states that a request for exemption under section
905(j)(3) of the FD&C Act (21 U.S.C. 387e(j)(3)) may be made only by
the manufacturer of a legally marketed tobacco product for a minor
modification to that tobacco product and that the manufacturer must
submit the request and all information supporting it to FDA. The
request must be made in an electronic format that FDA can process,
review, and archive (or a written request must be made by the
manufacturer explaining in detail why the manufacturer cannot submit
the request in an electronic format and requesting an alternative means
of submission to the electronic format).
An exemption request must contain: (1) The manufacturer's address
and contact information; (2) identification of the tobacco product(s);
(3) a detailed explanation of the purpose for the modification; (4) a
detailed description of the modification, including a statement as to
whether the modification involves adding or deleting a tobacco
additive, or increasing or decreasing the quantity of the existing
tobacco additive; (5) a detailed explanation of why the modification is
a minor modification of a tobacco product that can be sold under the
FD&C Act; (6) a detailed explanation of why a report under section
905(j)(1) of the FD&C Act intended to demonstrate substantial
equivalence is not necessary to ensure that permitting the tobacco
product to be marketed would be appropriate for protection of the
public health; (7) a certification (i.e., a signed statement by a
responsible official of the company) summarizing the supporting
evidence and providing the rationale for the official's determination
that the modification does not increase the tobacco product's appeal to
or use by minors, toxicity, addictiveness, or abuse liability; (8)
other information justifying an exemption; and (9) an environmental
assessment (EA) under part 25 (21 CFR part 25) prepared in accordance
with the requirements of Sec. [thinsp]25.40.
The National Environmental Policy Act of 1969 (NEPA) (42 U.S.C.
4321-4347) states national environmental objectives and imposes upon
each Federal Agency the duty to consider the environmental effects of
its actions. Section 102(2)(C) of NEPA requires the preparation of an
environmental impact statement for every major Federal action that will
significantly affect the quality of the human environment.
FDA's NEPA regulations are contained in part 25. All applications
for exemption from substantial equivalence require the submission of an
EA. An EA provides information that is used to determine whether an FDA
action could result in a significant environmental impact. Section
25.40(a) and (c) specifies the content requirements for EAs for
nonexcluded actions.
The information required by Sec. [thinsp]1107.1(b) is submitted to
FDA so FDA can determine whether an exemption from substantial
equivalence to the product is appropriate for the protection of the
public health. Section 1107.1(c) states that FDA will review the
information submitted and determine whether to grant or deny an
exemption based on whether the criteria in section 905(j)(3) of the
FD&C Act are met. FDA may request additional information if necessary
to make a determination and may consider the exemption request
withdrawn if the information is not provided within the requested
timeframe.
Section 905(j)(1)(A)(ii) of the FD&C Act states that if an
exemption has been requested and granted, a report must be submitted to
FDA that demonstrates that the tobacco product is modified within the
meaning of section 905(j)(3), the modifications are to a product that
is commercially marketed and in compliance with the requirements of the
FD&C Act, and all of the modifications are covered by exemptions
granted by the Secretary of Health and Human Services (the Secretary)
under section 905(j)(3).
In the Federal Register of September 13, 2018 (83 FR 46501) FDA
published a 60-day notice requesting public comment on the proposed
collection of information. Two PRA related comments were received,
which inquired about how FDA formulated the PRA estimates. In response
to the questions related to the PRA estimates, these estimates are
based on our experience. To date, the annual number of exemption
requests has been lower than the estimate of 812 respondents in this
notice (https://www.accessdata.fda.gov/scripts/fdatrack/view/track.cfm?program=ctp&id=%20CTP-OS-total-exemption-from-SE-since-Program-Inception), but the Agency expects that the number of exemption
requests could increase as applicants begin to submit such requests for
tobacco products subject to the final deeming rule. The estimated
number of respondents is intended to reflect that potential. As noted
in the comments, the exemption request is anticipated to take less time
than the other premarket applications, and FDA believes that 24 hours
average burden per response reflects the experience to date.
Along with commenting on the PRA estimates, these comments also
state that the Agency should provide additional details on exemption
requests and develop categories of exemptions. FDA appreciates these
comments but notes that consideration of such new processes is outside
the scope of the present information collection. FDA will continue to
consider these comments as appropriate in future rulemakings.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total annual burden per
21 CFR section and activity respondents responses per responses response (in Total hours
respondent \2\ hours)
----------------------------------------------------------------------------------------------------------------
Sec. 1107.1(b) Optional Preparation of Tobacco Product Exemption From Substantial Equivalence Request
Including Sec. 25.40 Preparation of an Environmental Assessment
----------------------------------------------------------------------------------------------------------------
21 CFR 1107.1(b)--Preparation of 812 1 812 24 19,488
tobacco product exemption from
substantial equivalence request
and 21 CFR 25.40--Preparation
of an environmental assessment.
-------------------------------------------------------------------------------
Total Hours (Sec. .............. .............. .............. .............. 19,488
1107.1(b)).................
----------------------------------------------------------------------------------------------------------------
[[Page 26125]]
Sec. 1107.1(c) Preparation of Additional Information for Tobacco Product Exemption From Substantial
Equivalence Request
----------------------------------------------------------------------------------------------------------------
21 CFR 1107.1(c)--Preparation of 244 1 244 3 732
additional information for
tobacco product exemption from
substantial equivalence request
-------------------------------------------------------------------------------
Total Hours (Sec. .............. .............. .............. .............. 732
1107.1(c)).................
----------------------------------------------------------------------------------------------------------------
Section 905(j)(1)(A)(ii) of the FD&C Act: If exemption granted, report submitted to demonstrate tobacco product
is modified under section 905(j)(3), modifications are to a product that is commercially marketed and compliant,
and modifications covered by exemptions granted by Secretary under section 905(j)(3)
----------------------------------------------------------------------------------------------------------------
Abbreviated report submitted to 1217 1 1217 3 3,651
demonstrate tobacco product is
modified under section
905(j)(3), modifications are to
a product that is commercially
marketed and compliant, and
modifications covered by
exemptions granted by Secretary
under section 905(j)(3)........
-------------------------------------------------------------------------------
Total Hours (section .............. .............. .............. .............. 3,651
905(j)(1)(A)(ii)) of the
FD&C Act...................
-------------------------------------------------------------------------------
Total Hours Exemptions .............. .............. .............. .............. 23,871
From Substantial
Equivalence
Requirements...........
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
FDA estimates that we will receive 812 exemption requests under
Sec. 1107.1(b) for 24 hours per response including EA for a total of
19,488 hours. Since an EA is required for each Sec. 1107.1(b)
(Optional Preparation of Tobacco Product Exemption From Substantial
Equivalence Request), the burden per response for EAs (12 hours) has
been combined with the 12 hours for an SE request for a total of 24
hours per response.
FDA further estimates that we will receive 244 submissions
requiring additional information in support of the initial exemption
request, and it is expected that it will take an average of 3 hours to
prepare the additional information for a total of 732 hours.
FDA estimates that 1,217 respondents will prepare 1,217 responses
and each response will take approximately 3 hours to prepare, as
required by section 905(j)(1)(A)(ii) of the FD&C Act, for a total of
3,651 hours.
This collection of information requires a manufacturer to submit a
report at least 90 days prior to making an introduction or delivery for
introduction into interstate commerce for commercial distribution of a
tobacco product. Section 905(j)(1)(A)(ii) of the FD&C Act states that
if an exemption has been requested and granted, the manufacturer must
submit to FDA a report that demonstrates that the tobacco product is
modified within the meaning of section 905(j)(3), the modifications are
to a product that is commercially marketed and in compliance with the
requirements of the FD&C Act, and all the modifications are covered by
exemptions granted by the Secretary under section 905(j)(3). FDA
estimates the total hours for exemptions from Substantial Equivalence
Requirements will be 23,871 hours.
FDA's estimates are based on full analysis of economic impacts and
information gathered from other FDA-regulated products. Based on a
review of the currently approved information collection, we have made
no adjustments to our burden estimate.
Dated: May 30, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-11658 Filed 6-4-19; 8:45 am]
BILLING CODE 4164-01-P